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MYOCARDIAL INFARCTION 
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Objectives. Our aim was to determine the percent of patients 
with myocardial infarction who are treated with beta-adrenergic 
blocking agents in dosages proved to be effective in preventing 
death after a heart attack. 
Background. In the prospective randomized trials showing that 
beta-blocker treatment improves survival rates after myocardial 
infarction, relatively high dosages of these agents were used. 
However, it is not known whether these dosages are used in 
current clinical practice. 
Methods. In a retrospective analysis of clinical data from 606 
consecutive survivors of myocardial infarction at four university 
hospitals in three countries, we assessed the number of infarct 
survivors receiving prospectively defined "effective dosages" of 
beta-blockers. We defined these dosages as those that demon- 
strated improved survival rates of infarct survivors who received 
active drug in large, prospective, double-blind, placebo-controlled 
trials. 
Results. Only 58% of infarct survivors with no contraindica- 
tions to beta-blockers received these drugs at the time of hospital 
discharge, and only 11% received dosages equivalent o >50% of 
the effective dosages. Independent predictors of failure to pre- 
scribe beta-blockers to infarct survivors without contraindications 
to these drugs were the use of diuretic agents, transient heart 
failure, impaired left ventricular function and increased patient 
age. Among patients receiving beta-blockers, only the use of 
propranoiol predicted prescription of a low beta-blocker dosage. 
Conclusions. Failure to prescribe beta-blockers after myocar- 
dial infarction is common but in most cases is not due to clear 
contraindications. Many patients not receiving beta-blockers be- 
long to subgroups that would derive the greatest benefit from such 
treatment. Finally, even when beta-blockers are prescribed, the 
dosages used are considerably lower than those proved to be 
effective in preventing death after myocardial infarction. 
(J Am Coil Cardioi 1995;25"1327-32) 
Prospective randomized trials have shown that beta-blockers 
improve the long-term prognosis of patients with myocardial 
infarction (1): mortality, cardiac death and sudden cardiac 
death are reduced by 21%, 24% and 30%, respectively (1,2). In 
addition, treatment with beta-blockers reduces the risk of 
reinfarction by 25% (1). Therefore, infarct survivors who have 
no specific ontraindications to beta-blockers should routinely 
be offered such therapy (3,4). 
However, although data on the beneficial effects of beta- 
blockers have existed for almost 2 decades (5), many infarct 
survivors are not being treated with these agents. A recent 
survey of medical practices in 16 hospitals in Massachusetts (6) 
and two multicenter t ials in the United States (7) and Europe 
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(8) demonstrated that only 44% to 56% of patients were 
receiving beta-blocker therapy after a myocardial infarction. 
These numbers are surprising because clear contraindications 
to such treatment were found in only 18% of patients enrolled 
in prospective beta-blocker t ials (9,10). 
Although several studies have found predictors of failure to 
prescribe beta-blockers, including impaired left ventricular 
ejection fraction (11), evidence of heart failure (6,11) and 
increased patient age (6,12,13), we know of no published ata 
on the dosages of beta-blockers generally prescribed after a 
myocardial infarction. Such data are important because trials 
showing improvement in survival rates with beta-blocker t eat- 
ment invariably used relatively high dosages (9,14-16). There- 
fore, the aim of this study was to analyze the percent of infarct 
survivors who receive beta-blockers in dosages comparable to 
those proved to be effective in improving long-term survival. 
Methods  
We reviewed the files of consecutive patients discharged 
with a diagnosis of acute myocardial infarction from one 
American, one Mexican and two Israeli hospitals. The patients 
had been treated in wards of Internal Medicine and Cardiology 
at the State University of New York Health Science Center, 
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Syracuse, New York (166 patients), lnstituto Nacional de 
Cardiologia Ignacio Chavez, Mexico City, Mexico (71 pa- 
tients), the Chaim Sheba Medical Center, Tel-Hashomer, 
Israel (113 patients) and the Souras~-Tel Aviv Medical Cen- 
ter, Tel Aviv, Israel (256 patients) during the last 6 months of 
1993. 
Definitions. We defined contraindication to beta-blocker 
treatment according to the criteria used in the large prospec- 
tive studies on beta-blocker t eatment after myocardial infarc- 
tion (9,10,14,15). Thus, the presence of any of the following 
classified a patient as having contraindications: 1) a diagnosis 
(or clinical signs) of asthma or chronic obstructive lung dis- 
ease; 2) heart failure not controlled with diuretic drugs (furo- 
semide >80 mg/day) or with digoxin and diuretic drugs (any 
dosage); 3) the presence of atrioventricular (AV) block of any 
degree, heart rate <50 beats/min or systolic blood pressure 
<100 mm Hg (unless transient) before treatment with beta- 
blockers. 
The type and daily dosage of beta-blocker recommended at 
the time of hospital discharge were recorded as a percent on 
the basis of the "effective dosage." We defined "demonstrated 
effective dosages," (or, in short, "effective dosages") of beta- 
blockers as the dosages used in large prospective double-blind 
placebo-controlled beta-blocker trials that demonstrated im- 
proved survival in the patients receiving active drug. Accordingly, 
we defined "effective dosages" as follows: propranolol, 160 m~' 
day (9,15); metoprolol, 200 mg/day (14), or atenolol, 100 mg/day 
(17). We found no patients receiving timolol, sotalol, pindolol, 
practolol, oxprenolol or acebutolo[ at the time of hospital dis- 
charge. 
Statistics. The following variables were analyzed for their 
value in predicting absence of beta-blocker t eatment among 
patients without contraindications to beta-blockers: age, gen- 
der, hospital from which the patients were discharged, infarct 
location, Q wave infarction, left ventricular ejection fraction, 
results of coronary angiography, revascularization procedures, 
lowest heart rate recorded, presence of arrhythmias, pulmo- 
nary edema, heart failure and hypotension atany time during 
the hospital stay and use of other medication (diuretic drugs, 
calcium channel blocking agents, vasodilators, digoxin, ni- 
trates, aspirin or anticoagulant agents). Univariate predictors 
were examined by chi-square test for discrete variables and 
t test or analysis of variance for continuous variables. The 
results are given as odd ratio and p values. In addition to the 
variables mentioned, the type of beta-blocker used was tested 
for prediction of the dosage of beta-blocker (expressed as 
percent of effective dosage) prescribed. Pearson correlation 
was performed to evaluate the relation between two continu- 
ous variables. Multivariate predictors of failure to prescribe 
beta-blockers were selected by logistic regression; stepwise 
regression was used to define the most important independent 
predictor of the dosage of beta-blocker prescribed. Statistical 
significance was defined as a p value <0.05. 
Resu l ts  
Patient characteristics. During the study period, 606 pa- 
tients (mean [+_SD] age 64 +_ 14 years) were discharged after 
a myocardial infarction. Of these, 69% were male and 78% 
were <75 years old; in 31%, the infarct involved the anterior 
wall, in 59% it was inferior or inferoposterolateral and in 9% 
it was not localized. A Q wave infarction occurred in 45% of 
patients. Transient complications among infarct survivors in- 
cluded bradyarrhythmias in 22%, atrial or ventricular tachya- 
rrhythmias in 16%, hypotension i  10%, heart failure in 21%, 
pulmonary edema in 14% and cardiogenic shock in 2%. 
Data on left ventricular ejection fraction were available for 
54% of patients. The mean ejection fraction was 45 _+ 19%; 
90% and 71% of infarct survivors, respectively, had an ejection 
fraction >30% and >40%. Cardiac catheterization was per- 
formed during the hospital stay for myocardial infarction in 
49% of patients: Single-, double- and triple-vessel coronary 
disease was found in 41%, 29% and 23%, respectively, ofthese 
patients, and normal coronary arteries were reported in 6%. 
During the hospital stay for infarction, coronary bypass urgery 
was performed in 7% of infarct survivors (14% of those 
undergoing catheterization); coronary angioplasty was at- 
tempted in 15% and was successful in 12% (29% and 23%, 
respectively, of those undergoing catheterization). 
Treatment with beta-blockers after myocardial infarction. 
Contraindications to treatment with beta-blockers were 
present in 18% of infarct survivors. They included bronchial 
asthma or chronic obstructive lung disease in 7%, heart failure 
controlled only with the use of >80 mg of furosemide daily or 
the use of digoxin in 7%, sinus bradycardia in 4%, AV block in 
5% and hypotension atthe time of hospital discharge in 5%. 
Many patients had more than one contraindication. 
Only 51% of all infarct survivors received beta-blocker 
treatment a the time of hospital discharge. Moreover, only 6% 
of all infarct survivors received an effective dosage of these 
drugs (Fig. 1). The percent of infarct survivors receiving 
beta-blockers was similar in all four hospitals (48%, 53% and 
57% in the Israeli, the American and the Mexican hospitals, 
respectively; p = NS). However, the type of beta-blocker used 
varied among hospitals: Metoprolol was used in >85% of 
treated patients in the American and Mexican hospitals, 
whereas propranolol was the drug most commonly used (63% 
of treated patients) in the two Israeli hospitals. Atenolol was 
given to 26%, 11% and 5% of patients receiving beta-blockers 
in the Israeli, American and Mexican hospitals, respectively. 
The mean daily dosages used were 105 _+ 56 mg of metoprolol, 
50 _+ 34 mg of propranolol and 65 + 57 mg/day of atenolol. 
Except for atenolol, which tended to be used in a higher dosage 
in the American hospital (111 _+ 122 mg/day, p : 0.05), the 
dosage of beta-blockers prescribed for infarct survivors was 
similar in the four hospitals tudied (p = 0.2 and p = 0.13 for 
propranolol and metoprolol, respectively). 
Although 82% of infarct survivors had no contraindications 
to beta-blocker treatment, only 58% of this group received 
beta-blockers. Moreover, most patients receiving beta-blockers 
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Figure 1. Distribution of infarct survivors according to the dosage of 
beta-blocker prescribed at the time of hospital discharge. Dosages of 
beta-blockers are shown as percent of effective dosage (see Methods 
for definition of effective dosage). Solid bars = all patients surviving a 
myocardial infarction; open bars - all infarct survivors who had no 
contraindications to beta-blocker treatment. 
received a dosage significantly lower than those proved to be 
effective in preventing death (Fig. 1): Sixty-seven percent of 
infarct survivors without contraindications to beta-blockers 
(and 61% of those <70 years old) received a dosage quivalent 
to -<25% of the effective dosage of beta-blockers, whereas a 
dosage equivalent o >50% of the effective dosage was given to 
only 11% of infarct survivors without contraindications to 
beta-blockers regardless of age. 
Use of diuretic agents was the most important independent 
predictor of failure to prescribe beta-blockers to infarct survi- 
vors without contraindications to beta-blockers (Table 1). 
Other variables representing left ventricular dysfunction (tran- 
sient or compensated heart failure, left ventricular ejection 
fraction <30% or pulmonary edema during the hospital stay) 
also predicted failure to prescribe beta-blockers at the time of 
hospital discharge (Table 1). Of note, persistent left heart 
failure despite treatment would classify a patient as having 
contraindications to beta-blockers. 
We found no significant correlation between any of the 
variables predicting failure to prescribe beta-blockers (Table 1) 
and the beta-blocker dosage actually prescribed (Table 2). By 
Pearson analysis, no correlation was found between the last 
heart rate recorded and the dose of beta-blocker prescribed. 
The only independent variable that predicted use of low (or 
high) beta-blocker dosage was the type of beta-blocker used 
(Table 2): The mean dosage of propranolol was equivalent o 
<33% of the effective dosage, whereas patients receiving 
metoprolol received (on average) the equivalent of 50% of the 
effective dosage. Finally, the only variable that predicted the 
use of propranolol (rather than metoprolol or atenolol) was 
the use of diuretic drugs. 
Table 1. Predictors of Treatment With Beta-Blockers Among 
Infarct Survivors Without Contraindications 
Variable Odds Ratio (95% confidence limits) 
Univariate Analysis 
Use of diuretic drugs 
Transient heart failuret 
Age >70 years 
LVEF not measured 
Use of calcium channel blockers 
Pulmonary edema 
LVEF <30% 
Successful PTCA 
Electrical complications 
Female gender 
0.25 (0.15-0.42)* 
0.27 (0.16-0.47)* 
0.30 (0.20-0.44)* 
0.45 (0.31-0.64)* 
0.45 (0.3l-0.66)* 
0.33 (0.16-0.69):[: 
0.32 (0.11-0.87)§ 
0.60 (0.34-1.05)[[ 
0.62 (0.38-1.04)1[ 
0.69 (0.47-1.03)11 
Multivariate Analysis (logistic regression) 
Age >70 years 0.62 (0.50-0.87):I: 
Use of diuretic drugs 0.66 (0.50-0.88)~: 
LVEF <30% 0.76 (0.62-0.93)§ 
Transient heart failure 0.64 (0.4%0.88)§ 
An odds ratio value <1 denotes that the respective variable predicted failure 
to prescribe beta-blockers: *p < 0.0001. tPersistent heart failure despite 
treatment would classify a patient as having a contraindication to beta-blocker 
therapy. ;p < 0.005. §p < 0.05. liP - 0.07; all other variables tested (see 
Methods) did not significantly predict the use of beta-blockers. LVEF = left 
ventricular ejection fraction; PTCA - percutaneous transluminal coronary 
angioplasty. 
Discuss ion  
Although beta-blockers should be part of the standard 
long-term treatment after a myocardial infarction (3,4), 
roughly 50% of >600 patients surviving a myocardial infarc- 
tion in three countries were discharged without such treat- 
ment. These figures are similar to those reported in multi- 
center trials (7,8). However, the main finding in our study is 
that failure to recommend beta-blockers at the time of hospital 
discharge is typically not due to clear contraindications. More- 
Table 2. Percent of Effective Dosage of Beta-Blockers Administered 
to Infarct Survivors Without Contraindications 
Percent of Effective Dosage* (mean _+ SD) 
Univariate Analysis 
City 
Tct Aviv 42 _+ 27] p < 0.01 
Syracuse, New York 60 -+ 55 p < 0.05 
Mexico City 44 _+ 18] 
Type of beta-blocker 
Metoprolol 52 _+ 28] p < 0.0005 
Propranolol 31 _+ 21 p < 0.0005 
Atenolol 65 + 571 
Multivariate Analysis (stepwise regression) 
Type of beta-blocker p < 0.0001 
*See Methods for definition of effective dosage. No other variable tested 
(Table 1) correlated significantly with the prescribed osage of beta-blocker. 
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over, many of the patients not receiving beta-blockers belong 
to patient subgroups that would derive the greatest benefit 
from such treatment. Finally, even when beta-blockers are 
prescribed, the dosages used are considerably smaller than 
those proved to be effective by prospective trials, with only 6% 
of infarct survivors receiving effective dosages. 
What are effective dosages of beta-blockers? We defined as 
effective only those dosages proved to be effective in reducing 
mortality in prospective, randomized, ouble-blind placebo- 
controlled trials (9,14,15). It is possible that lesser dosages are 
also effective in prolonging survival after infarction, but this 
hypothesis remains to be proved. 
According to our definition, dosages of metoprolol, 
200 rag/day (14), and propranolol, 160 rag/day (15), repre- 
sented effective doses. However, higher dosages of propranolol 
(180 to 240 rag/day) were prescribed to the majority of patients 
in the Beta-blocker Heart Attack Trial (9). Thus, we may have 
overestimated the low percent of patients receiving effective 
dosages of propranolol in our study. 
Nine percent of patients in our study received atenolol. For 
these patients, we considered effective adosage of 100 rag/day, 
a regimen that has been found (17) to have effects on the 
1-year survival of infarct survivors comparable to those of 
160 mg/day of propranolol. However, those data come from a 
small study with a high withdrawal rate (17). Also, 100 rag/day 
of atenolol decreased the 1-year cardiovascular mortality in the 
ISIS-I study (18), but the randomization period in that study 
was limited to the in-hospital period. In fact, only 35% of 
patients in ISIS-1 received long-term treatment with beta- 
blockers. Therefore, our definition of 100 rag/day of atenolol as 
effective dosage was based mainly on published data on 
"equipotency" with propranolol and metoprolol (19-21). 
However, these quipotency data were derived from the drugs' 
effects on blood pressure (19) and on tachycardia (induced by 
exercise [19,20] or isoproterenol infusion [21]) and do not 
necessarily apply to postinfarction patients. 
Why are so many infarct survivors discharged without 
beta-blocker therapy? Only a minority of infarct survivors 
have clear contraindications to beta-blocker treatment. Such 
patients comprised only 18% of our study group and of those 
in the largest beta-blocker t ials (9,10). If diabetes and periph- 
eral vascular disease are added to the list of contraindications, 
up to 27% of infarct survivors may be considered to have 
contraindications (22). However, published ata suggest that 
infarct survivors with these conditions should not be deprived 
of the potential benefits of beta-blocker treatment. Although 
some studies (10,14) excluded patients with severe intermittent 
claudication, peripheral vascular disease itself was not a con- 
traindication to enrollment in large beta-blocker t ials (9,14). 
Yet symptomatic deterioration of peripheral vascular disease 
as a reason for drug discontinuation was not more common in 
patients receiving beta-blockers than in those receiving pla- 
cebo (9,14,23). Moreover, reduction of mortality and reinfarc- 
tion rates by beta-blocker treatment appears to be especially 
pronounced in diabetic patients (24-27). 
In our study, only 58% of infarct survivors without contra- 
indications to beta-blockers were receiving these drugs. Pre- 
dictors of failure to prescribe beta-blockers included the 
presence of impaired left ventricular function (as indicated by 
treatment with diuretic agents, transient or controlled heart 
failure or left ventricular ejection fraction <30%) and in- 
creased patient age. It is plausible that physicians avoid 
recommending beta-blockers to patients with impaired left 
ventricular function and to elderly patients, mainly because of 
their concern for potential iatrogenic omplications. These 
observations deserve further comment. 
Infarct survivors with impaired left ventricular function 
are less likely to receive beta-blockers. Is that justifiable? Our 
results are in accordance to the report by Lichstein et al. (11) 
on the use of beta-blockers ina multicenter trial. In that study 
(11), the percent of infarct survivors receiving beta-blockers 
ranged from 57% among patients with good left ventricular 
function to 21% among patients with a left ventrieular ejection 
fraction <30%. 
The danger of causing overt heart failure with beta-blockers 
appears to be overestimated: The rate of precipitation ofheart 
failure of enough severity to warrant drug discontinuation was 
<5% in the large beta-blocker trials (9,10,14). Even among 
infarct survivors with marked cardiomegaly (28) or with a 
history of congestive heart failure (23), clinical heart failure 
was rarely precipitated (in 8% and 15% of patients, respec- 
tively) and was not more common than in patients treated with 
placebo (23,28). In fact, some data (11) suggest hat beta- 
blocker treatment of postinfarction patients with impaired 
ejection fraction may prevent, rather than precipitate, the 
development of clinical heart failure. Finally, by withholding 
beta-blocker treatment from patients with impaired left ven- 
tricular function, we may be depriving the very patients who 
have the most to gain from such therapy (2,28,29). The large 
prospective beta-blocker trials did not provide data on the 
ejection fraction of randomized patients (9,10,14). However, 
other variables that correlate with large infarcts (i.e., higher 
serum enzyme levels [14] or cardiomegaly [9,10] invariably 
correlated with a greater absolute reduction in mortality with 
beta-blocker therapy (9,10,14). For example, in the Norwegian 
Multicenter Study, 2 lives were saved for each 100 patients with 
normal heart size treated with timolol, whereas among patients 
with cardiomegaly, 10 lives were saved per 100 patients treated 
(28). 
Should elderly patients be treated with beta-blockers after 
myocardial infarction? Physicians eem to be reluctant o 
prescribe beta-blockers to elderly patients (6,12). In our study 
only 38% of infarct survivors without contraindications to 
beta-blockers who were ->70 years old received these agents, 
whereas 68% of similar younger patients received such treat- 
ment. 
Although the value of beta-blockers for improving survival 
in elderly infarct survivors remains to be proved (prospective 
beta-blocker trials excluded patients >70 (9,14,15) or 75 
(10,16,30) years old, subgroup analysis of most prospective 
trials does not suggest adecreased benefit from beta-blockade 
with increasing age (9,10,14,16). In fact, it is the youngest 
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patients (those <50 [2], <60 [23] or <65 [14] years old) who 
may, because of their generally good prognosis, derive the 
smallest benefit from beta-blocker treatment. Finally, use of 
beta-blockers was the best predictor of survival among patients 
who were >70 years of age at the time of myocardial infarction 
in a nonrandomized study (12), and a trend toward increased 
survival with beta-blocker use was also reported for patients 
>75 years old (13). 
Bradycardia nd symptomatic peripheral vascular disease 
seem to be the only adverse effects of beta-blockers more 
common with increasing age (31). Therefore, with close follow- 
up, increased age should not be viewed as a contraindication to 
beta-blockade (31). 
Only a minority of infarct survivors receive effective dos- 
ages of beta-blockers. To our knowledge, there have been no 
previous published ata on the dosages of beta-blockers com- 
monly prescribed after infarction. Our observation that only 
6% of patients received a dosage equivalent to those proved 
effective in preventing death after infarction should be con- 
firmed by further studies. 
The only independent predictor of prescription of a low 
dosage was the type of beta-blocker used: Patients receiving 
propranolol received a significantly lower dosage. This trend 
was apparently influenced by the dose of beta-blockers avail- 
able in tablets: A 10 mg tablet of propranolol isequivalent to 
only 6% of the effective dosage (32). In contrast, patients 
receiving the smallest metoprolol dose available in tablets (i.e., 
50 mg [32]) are receiving 25% of the effective daily dosage. Our 
study did not examine why physicians prefer one beta-blocker 
over another. It is possible that propranolol was preferred for 
patients conceived to be at higher isk for adverse ffects, as 
suggested by the more common use of propranolol (rather 
than other beta-blockers) among patients receiving diuretic 
agents. 
Limitations and clinical implications of our study. Our 
study focused on the clinical practices of four hospitals in three 
countries, and the data may not apply to the treatment of 
infarct survivors elsewhere. However, the percent of infarct 
survivors receiving beta-blockers in our study was very similar 
to that reported in large studies (7,8,33). Also, we limited our 
evaluation of drug treatment tothat recommended at the time 
of hospital discharge; thus, it is possible that more beta- 
blockers were given during follow-up visits. However, in the 
European Cooperative Study (8), the percent of infarct survi- 
vors receiving beta-blockers at 3 months and 1 year after 
infarction was essentially that reported at the time of hospital 
discharge. In addition, arecent survey of treatment practices in 
England (22), indicated that family physicians were adminis- 
tering beta-blockers to only 39% of infarct survivors without 
contraindications. Therefore, we believe that our results re- 
garding the underuse of beta-blockers after myocardial infarc- 
tion represent common clinical practice and identify a major 
gap between what we have learned from prospective trials and 
current reatment of patients. This gap ought o be closed by 
continuing medical education. Alternatively, prospective stud- 
ies should be made of infarct survivors randomized to receive 
either the "effective dosage" defined by large clinical trials or 
the relatively low dosage of beta-blockers commonly used. 
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